How Tsai was paid
$301,522 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Total |
|---|---|---|---|---|
| Chun-Hsien TsaiPresident & Chief Executive Officer | $122,517 | $115,313 | $63,692 | $301,522 |
| Hsin-Liang LeeChief Financial Officer | $79,927 | — | $13,696 | $93,623 |
| Meng-Lin SungFormer Chief Financial Officer | $21,553 | $9,369 | — | $30,922 |
| Lawrence K. LinEVP of Operations | $84,000 | — | — | $84,000 |
What changed and why
- $302K$301,522 was CEO Chun-Hsien Tsai’s total compensation in 2024, down from $1,285,023 in 2023.
- $115K$115,313 of the CEO’s 2024 compensation was a bonus, representing the largest component.
- $63,692$63,692 was the grant-date fair value of the CEO’s 2024 stock awards.
- $216K$216,102 was total compensation for the three non-PEO named executives in 2024.
- 2024 compensation emphasized non-financial measures including clinical development progress and commercialization progress.
- $480KThe CEO’s monthly salary increased to NT$479,810 effective September 1, 2024.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.